Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @CellTherapyIC
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @CellTherapyIC
-
In this
@BioProcessIntl piece, authors discuss the use of analytical assays in process development and manufacturing of cell and gene therapieshttps://informaconnect.com/regulatory-landscape-assay-development-cgt-products/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The future is bright for antibody-based & cellular immunotherapies, with the technologies of bispecifics and CAR-Ts converging. This whitepaper looks at the latest advances & challenges in immuno-oncology drug development http://spr.ly/6017158A1
#oncology#futurism#antibodiespic.twitter.com/xbOETRDI7w
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Behnam Ahmadian, Global Head of Process Development at Lonza, discusses the scaling of manufacturing, process development challenges,
#automation and the latest#technologies for#cell therapies in this exclusive interviewhttps://youtu.be/E5kVbsLhQvUHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CAR-T and T-cell receptor
#cell therapies are some of the most exciting emerging therapies on the market today. This whitepaper discusses recent developments in CAR and TCR#engineering and the overlap with#antibody engineeringhttps://informaconnect.com/tcr-car-t-cell-therapies-engineering-strategies-whitepaper/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
How are leading biotech and pharma organizations successfully implementing
#DiversityandInclusion initiatives? Here are 6 best practices chosen by Edie Stringfellow@MassBio#BiotechWeekBoston http://spr.ly/601115853 pic.twitter.com/u4DGD0272R
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
When developing a new therapy how do you keep in complete control of its manufacturing? This whitepaper looks at what to consider - whatever path you take.http://spr.ly/601015rtp
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
62% of respondents
#manufacture their cell and#gene therapies both internally and externally http://spr.ly/60161585r pic.twitter.com/NxE4IypMKU
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Heidelberg-based
@NCT_HD have created tumor-targeted oncolytic virus vaccines using encoded bispecific T-cell engagers. In this recorded webinar, Christine Engeland, MD, PhD explains their journey.http://spr.ly/6014158kIHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The high costs of
#CART cell therapy puts it out of reach for many cancer patients. How can it be made more affordable? We asked three industry experts http://spr.ly/6019158Z3 pic.twitter.com/er0XgVzseu
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
In this exclusive interview
@RoosterBio founder Jon Rowley explores the decision making process for choosing a manufacturing platform for cell therapies, and how that impacts COGS http://spr.ly/6013158ov#health#medicine#regenmed#cellHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Behnam Ahmadian, Global Head of Process Development at Lonza, discusses the scaling of manufacturing, process development challenges,
#automation and the latest#technologies for#cell therapies in this exclusive interviewhttps://youtu.be/E5kVbsLhQvUHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Chris Gemmiti, VP of Operations
@SentienBiotech discusses the highs and lows of mesenchymal#StemCells and whether their peak is yet to come. Read more http://spr.ly/6016158op pic.twitter.com/ihPRb9FQT5
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The future is bright for antibody-based & cellular immunotherapies, with the technologies of bispecifics and CAR-Ts converging. This whitepaper looks at the latest advances & challenges in immuno-oncology drug development http://spr.ly/6014158or
#oncology#futurism#antibodiespic.twitter.com/HDQ2iReHlz
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Can viruses be used to create tumor-targeted vaccines? In an on-demand webinar, Christine Engeland, MD, PhD
@NCT_HD explains how they have done just that, by encoding bispecific T-cell engagers within measles virus vectors. http://spr.ly/6010158W4 pic.twitter.com/lULn7WvO87
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Autologous cell therapies carry several challenges to commercialization, including high costs, the risks of manual processing, and compliance with strict timelines. This
@BioProcessIntl eBook presents two perspectives on addressing these challengeshttps://informaconnect.com/autologous-cell-therapies-commercialization-strategies/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Where do you start in setting up manufacturing for a new therapy? Insourcing or outsourcing - and when is best to decide? This whitepaper presents best practices and case studies. http://spr.ly/601615Hai pic.twitter.com/lYcJmquKhY
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
62% of respondents
#manufacture their cell and#gene therapies both internally and externally http://spr.ly/6019158l7 pic.twitter.com/gzk6G2NUxm
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Gene therapies could revolutionize treatment of genetic disease, but how should the cost-effectiveness of these drugs be measured? We explore -> http://spr.ly/60121diIs
#gene#healthcareHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Knud Jensen, Professor, Department of Chemistry at
@uni_copenhagen, discusses how can academia and biotechs can work better together to both benefithttps://www.youtube.com/watch?v=3qZZxJ37FgU …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Autologous cell therapies carry several challenges to commercialization, including high costs, the risks of manual processing, and compliance with strict timelines. This
@BioProcessIntl eBook presents two perspectives on addressing these challengeshttps://informaconnect.com/autologous-cell-therapies-commercialization-strategies/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.